Trendlines Medical Singapore and A*ccelerate establish partnership to jointly develop and commercialise medical technologies

Misgav, Israel and Singapore, 11 November 2018 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries, **"Trendlines"** or the "**Group**"), a leading Israeli-based investment and innovation commercialisation company focused on early-stage, high growth medical and agricultural technologies, announced today that its wholly owned subsidiary, Trendlines Medical Singapore Pte. Ltd. ("**Trendlines Medical Singapore**") has entered into a Memorandum of Understanding ("**MOU**") with Accelerate Technologies Pte Ltd (**A*ccelerate**) for both parties ("**the Parties**") to collaborate and explore potential joint research and development initiatives in several medical technology areas.

Under the MOU, Trendlines Medical Singapore and A*ccelerate will work together to identify technology from A*STAR with the intention of spinning-off up to five start-up companies that will benefit from Trendlines Medical Singapore's expertise in medical device incubation and A*ccelerate's technology development capability. A*ccelerate will contribute to the technology and product development for each start-up company, and Trendlines Medical Singapore will invest and incubate these start-up companies in the same way as our current and other companies. There will be no additional costs to Trendlines Medical Singapore as a result of this partnership. For the initial activity, the Parties have identified projects in the field of ultrasound guided therapies, neurorehabilitation, radiology, ophthalmology, urology, and gastroenterology to commence this partnership.

A*ccelerate is the rebranded entity of what was formerly known as ETPL, the commercialisation arm of the Agency for Science, Technology and Research ("**A*STAR**"). It supports A*STAR in transforming the economy by driving innovation and commercialising its research outcomes. A*STAR is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology.

Chairman of Trendlines Medical Singapore Todd Dollinger commented, "The partnership with A*STAR and A*ccelerate deepens our resolve to strengthen our partnership with

hospitals and research institutes to boost the medical device start-up eco-system in Singapore. It's the shared mission of A*STAR and Trendlines to advance science and develop innovative technology to improve lives, and we are pleased that Trendlines will play a meaningful role in the incubation and commercialisation of medical technologies in the process for Singapore to achieve this mission."

According to Philip Lim, Chief Executive of A*ccelerate, "We are working to ensure that A*STAR spinoffs get the most traction in the market. To do this, we must collaborate with the best partners to help co-create and grow our startups. A*ccelerate will focus on incubating technologies and developing products and services. Trendlines' ability to effectively incubate medical technology companies, will compliment this nicely."

Trendlines Medical Singapore CEO Eric Loh added, **"**This collaboration will leverage on A*ccelerate's productization capabilities and Trendlines' experience and proven track record in identifying, incubating, and developing medical technology companies. The initial intellectual property assets that we have identified can serve to address significant clinical needs with substantial market potential. We are excited to work closely with A*ccelerate to further develop these assets, commercialise products and solutions and benefit both patients and investors."

-The End-

About Trendlines Medical Singapore Pte. Ltd.

Trendlines Medical Singapore (www.trendlines.com/trendlines-medical-singapore/) is a medical technology start-up incubator established by Trendlines and B. Braun Melsungen AG, one of the world's leading medical device companies. Trendlines Medical Singapore discovers, invests in, incubates, and provides a range of services to nurture and develop Singapore-based companies involved in novel medical devices and technologies with a view toward success in the global market.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialisation company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

About The Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR's R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

About A*ccelerate

A*ccelerate is the commercialisation arm of the Agency for Science, Technology and Research (A*STAR), Singapore's lead agency for fostering world-class scientific research and talent. As a one-stop resource, A*ccelerate supports A*STAR in transforming the economy through driving innovation and commercialising its research outcomes.

Also known as Accelerate Technologies Pte Ltd, A*ccelerate enhances the research output of A*STAR scientists by translating and accelerating their inventions and intellectual capital into marketable products, processes and services. Through shaping and facilitating licensing deals and spin-offs, A*ccelerate actively engages industry leaders and players to commercialise A*STAR's technologies and apply them to building ecosystems that benefit business, industry and economy.

Investor Contact Information

Israel
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)